Amgen Buys UK’s Dark Blue Therapeutics for $840 Million to Boost Cancer Research

Amgen has acquired Dark Blue Therapeutics, a UK-based biotech firm, in a deal worth $840 million. This purchase aims to accelerate Amgen's advancements in developing innovative cancer therapies.